Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Inflammatory Bowel Disease.
作者信息
Boumitri Christine
机构信息
Assistant Professor Feinberg School of Medicine Northwestern Medicine Chicago, Illinois.
出版信息
Gastroenterol Hepatol (N Y). 2025 Jan;21(1):59-61.
Abstract
摘要
相似文献
1
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Inflammatory Bowel Disease.胰高血糖素样肽-1受体激动剂在炎症性肠病患者中的应用。
Gastroenterol Hepatol (N Y). 2025 Jan;21(1):59-61.
2
Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.胰高血糖素样肽-1受体激动剂在炎症性肠病中的安全性和有效性
Am J Gastroenterol. 2025 May 1;120(5):1152-1155. doi: 10.14309/ajg.0000000000003208. Epub 2024 Nov 14.
3
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.
4
Computational Design of Potent and Selective d-Peptide Agonists of the Glucagon-like Peptide-2 Receptor.基于计算设计的胰高血糖素样肽-2 受体强效高选择性 d-肽激动剂。
J Med Chem. 2023 Aug 10;66(15):10342-10353. doi: 10.1021/acs.jmedchem.3c00464. Epub 2023 Jul 25.
5
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.将二肽基肽酶-4抑制剂和胰高血糖素样肽-1激动剂重新定位为潜在的神经保护剂。
Neural Regen Res. 2019 May;14(5):745-748. doi: 10.4103/1673-5374.249217.
6
One step closer to solving the mystery of the anti-inflammatory effects of glucagon-like peptide-1 receptor agonists.
J Diabetes Investig. 2025 Feb;16(2):180-182. doi: 10.1111/jdi.14346. Epub 2024 Nov 13.
7
Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病患者中的作用：一项荟萃分析。
J Clin Pharm Ther. 2021 Dec;46(6):1650-1658. doi: 10.1111/jcpt.13502. Epub 2021 Aug 5.
8
Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.胰高血糖素样肽-1 受体激动剂：临床药理学的叙述性综述及其对围手术期实践的影响。
Anaesthesia. 2024 Jul;79(7):735-747. doi: 10.1111/anae.16306. Epub 2024 May 13.
9
Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue†.胰高血糖素样肽-1 受体激动剂可降低脱氢表雄酮诱导的多囊卵巢综合征小鼠的高胰岛素血症和高雄激素血症，并与减轻炎症和诱导白色脂肪组织棕色化有关。
Biol Reprod. 2023 Jun 9;108(6):945-959. doi: 10.1093/biolre/ioad032.
10
Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病和炎症性肠病中的应用。
Aliment Pharmacol Ther. 2024 Sep;60(5):620-632. doi: 10.1111/apt.18138. Epub 2024 Jun 27.
引用本文的文献
1
The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂在合并代谢性共病的炎症性肠病患者的IBD相关手术及IBD相关并发症中的作用：一项系统评价和荟萃分析
Front Med (Lausanne). 2025 Aug 21;12:1621958. doi: 10.3389/fmed.2025.1621958. eCollection 2025.
本文引用的文献
1
Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study.胰高血糖素样肽-1受体激动剂与炎症性肠病患者肠梗阻或肠阻塞风险增加无关——一项丹麦全国队列研究
Inflamm Bowel Dis. 2025 Jul 7;31(7):1961-1965. doi: 10.1093/ibd/izae276.
2
Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.GLP-1 激动剂对非糖尿病炎症性肠病患者代谢参数的疗效和安全性。
Dig Dis Sci. 2024 Dec;69(12):4437-4445. doi: 10.1007/s10620-024-08720-2. Epub 2024 Nov 8.
3
GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN.胰高血糖素样肽-1类似物的使用与炎症性肠病病情改善相关：Epi-IIRN的一份报告
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjae160.
4
GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD.胰高血糖素样肽-1受体激动剂不会增加炎症性肠病患者炎症性肠病病情加重的发生率。
Inflamm Bowel Dis. 2025 Feb 10;31(2):467-475. doi: 10.1093/ibd/izae250.
5
Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity.司美格鲁肽用于炎症性肠病合并肥胖患者减肥的有效性和安全性
Inflamm Bowel Dis. 2025 Mar 3;31(3):696-705. doi: 10.1093/ibd/izae090.
6
The alleviating effect and mechanism of GLP-1 on ulcerative colitis.GLP-1 对溃疡性结肠炎的缓解作用及其机制。
Aging (Albany NY). 2023 Aug 17;15(16):8044-8060. doi: 10.18632/aging.204953.
7
Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study.较高的内脏腹部脂肪组织质量与生物治疗起始时炎症性肠病患者的临床和内镜缓解率较低相关：星座研究的结果。
Gastroenterology. 2023 Oct;165(4):963-975.e5. doi: 10.1053/j.gastro.2023.06.036. Epub 2023 Jul 25.
8
Adipokines and Their Role in Intestinal Inflammation.脂肪细胞因子及其在肠道炎症中的作用。
Front Immunol. 2018 Oct 12;9:1974. doi: 10.3389/fimmu.2018.01974. eCollection 2018.
9
Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.炎症性肠病中的肥胖：流行病学、发病机制、疾病进程及治疗结果
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121. doi: 10.1038/nrgastro.2016.181. Epub 2016 Nov 30.
10
Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.体重指数增加与炎症性肠病患者对英夫利昔单抗的反应丧失时间提前有关。
Inflamm Bowel Dis. 2013 Sep;19(10):2118-24. doi: 10.1097/MIB.0b013e31829cf401.
Zotero 插件